metricas
covid
Buscar en
Gastroenterología y Hepatología
Toda la web
Inicio Gastroenterología y Hepatología Resolución de la enfermedad de Ménétrier tras la erradicación de la infecciÃ...
Journal Information
Vol. 27. Issue 6.
Pages 357-361 (January 2004)
Share
Share
Download PDF
More article options
Vol. 27. Issue 6.
Pages 357-361 (January 2004)
Full text access
Resolución de la enfermedad de Ménétrier tras la erradicación de la infección por Helicobacter pylori
Resolution of mÉnÉtrierx's disease after eradication of helicobacter pylori infection
Visits
8089
S.Santolaria Piedrafitaa,
Corresponding author
ssantolaria@able.es

Correspondencia: Dr. S. Santolaria Piedrafita. Sección de Aparato Digestivo. Hospital General San Jorge. Avda. Martínez de Velasco, s/n. 22004 Huesca. España.
, R.Conde Garcíaa, M.Abascal Agorretab, I.Domínguez Torresc, J.Ducóns Garcíaa, R.Guirao Larrañagaa, M.Montoro Hugueta
a Sección de Aparato Digestivo. Hospital San Jorge. Huesca. España
b Servicio de Anatomía Patológica. Hospital San Jorge. Huesca. España
c Servicio de Radiología. Hospital San Jorge. Huesca. España
This item has received
Article information
Resumen

La enfermedad de Ménétrier es una entidad clínica poco frecuente que se caracteriza por un engrosamiento de los pliegues gástricos, secundario a una hiperplasia de las células mucosas foveolares, frecuentemente asociada con pérdida de proteínas entéricas e hipoalbuminemia. Su etiología es desconocida, si bien en los últimos años se ha relacionado con la infección por Helicobacter pylori. Presentamos el caso clínico de un varón de 38 años con una gastroenteropatía «pierde proteínas» causada por la enfermedad de Ménétrier, en la cual la erradicación de la infección por H. pylori se siguió de una mejoría sintomática y de la resolución de la hipoalbuminemia. De acuerdo con el criterio de otros autores, opinamos que se debe investigar la presencia de infección por H. pylori en todos los pacientes con enfermedad de Ménétrier. En caso de confirmarse, la terapia erradicadora es la primera opción de tratamiento.

Ménétrier's disease is an infrequent clinical entity characterized by thickening of the gastric folds secondary to hyperplasia of the foveolar mucosa cells, frequently associated with loss of enteric proteins and hypoalbuminemia. Its etiology is unknown, although in the last few years it has been related to Helicobacter pylori infection. We present the case of a 38-year-old man with protein-losing gastroenteropathy caused by Ménétrier's disease, in whom eradication of H. pylori infection was followed by symptom improvement and resolution of hypoalbuminemia. In agreement with the criteria of other authors, we investigate the presence of H. pylori infection in all patients with Ménétrier's disease. When positive, the first-line treatment consists of eradication therapy.

Full text is only aviable in PDF
Bibliografía
[1.]
F. Villardell, et al.
Formas especiales de gastritis. Enfermedad de Ménétrier.
Enfermedades digestivas, pp. 689-697
[2.]
E. Bayerdorffer, M.M. Ritter, R. Hatz, W. Brooks, G. Ruckdeschel, M. Stolte.
Healing of protein losing hypertrophic gastropathy by eradication of Helicobacter pylori — is Helicobacter pylori a pathogenic factor in Ménétrier's disease?.
Gut, 35 (1994), pp. 701-714
[3.]
M. Kawasaki, K. Hizawa, K. Aoyagi, S. Nakamura, M. Fujishima.
Ménétrier's disease associated with Helicobacter pylori infection: resolution of enlarged gastric folds and hypoproteinemia after antibacterial treatment.
Am J Gastroenterol, 92 (1997), pp. 1909-1912
[4.]
D. Badov, J.R. Lambert, M. Finlay, N.D. Balazs.
Helicobacter pylori as a pathogenic factor in Ménétrier's disease.
Am J Gastroenterol, 93 (1998), pp. 1976-1979
[5.]
T. Shimoyama, S. Fukuda, M. Tanaka, T. Mikami, R. Yamagata, T. Yoshimura, et al.
Healing of cimetidine-resistant Menetrier's disease by erradication of Helicobacter pylori infection.
J Clin Gastroenterol, 27 (1998), pp. 348-350
[6.]
T. Kaneko, T. Akamatsu, A. Gotoh, K. Shimodaira, T. Shimizu, K. Kiyosawa, et al.
Remission of Ménétrier's disease after a prolonged period with therapeutic eradication of Helicobacter pylori.
Am J Gastroenterol, 94 (1999), pp. 272-273
[7.]
M. Raderer, G. Oberhuber, E. Templ, L. Wagner, R. Pötzi, F. Wrba, et al.
Successful symptomatic management of a patient with Ménétrier's disease with long-term antibiotic treatment.
Digestion, 60 (1999), pp. 358-362
[8.]
L.G. Madsen, M. Taskiran, J.L. Madsen, P. Bytzer.
Ménétrier's disease and Helicobacter pylori: normalization of gastrointestinal protein loss after eradication therapy.
Dig Dis Sci, 44 (1999), pp. 2307-2312
[9.]
G. Di Vita, R. Patti, F. Aragona, P. Leo, G. Montalto.
Resolution of Ménétrier's disease after Helicobacter pylori eradicating therapy.
Dig Dis, 19 (2001), pp. 179-183
[10.]
P.J. Dempsey, J.R. Goldenring, C.J. Soroka, I.M. Modlin, R.W. McClure, C.D. Lind, et al.
Possible role of transforming growth factor alpha in the pathogenesis of Ménétrier's disease: supportive evidence form humans and transgenic mice.
Gastroenterology, 103 (1992), pp. 1950-1963
[11.]
T.J. Sferra, B.R. Pawel, S.J. Qualman, B.U. Li.
Ménétrier disease of childhood: role of cytomegalovirus and transforming growth factor alpha.
J Pediatr, 128 (1996), pp. 213-219
[12.]
M. Stolte, C. Batz, S. Eidt.
Giant fold gastritis-a special form of Helicobacter pylori associated gastritis.
Z Gastroenterol, 31 (1993), pp. 289-293
[13.]
H.C. Wolfsen, H.A. Carpenter, N.J. Talley.
Ménétrier's disease: a form of hypertrophic gastropathy or gastritis?.
Gastroenterology, 104 (1993), pp. 1310-1319
[14.]
G.M. Groisman, J. George, D. Berman, N. Harpaz.
Resolution of protein-losing hypertrophic lymphocytic gastritis with therapeutic eradication of Helicobacter pylori.
Am J Gastroenterol, 89 (1994), pp. 1548-1551
[15.]
S.G. Meuwissen, B.U. Ridwan, H.J. Hasper, G. Innemee.
Hypertrophic protein-losing gastropathy. A retrospective analysis of 40 cases in The Netherlands. The Dutch Ménétrier Study Group.
Scand J Gastroenterol, 194 (1992), pp. 1-7
[16.]
S.S. Fieber, R.R. Rickert.
Hyperplastic gastropathy. Analysis of 50 selected cases from 1955-1980.
Am J Gastroenterol, 76 (1981), pp. 321-329
[17.]
D.G. Kelly, L.J. Miller, J.R. Malagelada, K.A. Huizenga, H. Markowitz.
Giant hypertrophic gastropathy (Ménétrier's disease): pharmacologic effects on protein leakage and mucosal ultrastructure.
Gastroenterology, 83 (1982), pp. 581-589
[18.]
R.M. Searcy, J.R. Malagelada.
Ménétrier's disease and idiopathic hypertrophic gastropathy.
Ann Intern Med, 100 (1984), pp. 565-570
[19.]
R.A. Komorowski, J.G. Caya, J.E. Geenen.
The morphologic spectrum of large gastric folds: utility of the snare biopsy.
Gastrointest Endosc, 32 (1986), pp. 190-192
[20.]
X. Calvet, I. Sanfeliu, E. Musulen, P. Mas, B. Dalmau, M. Gil, et al.
Evaluation of Helicobacter pylori diagnostic methods in patients with liver cirrhosis.
Aliment Pharmacol Ther, 16 (2002), pp. 1283-1289
[21.]
A. Vilella, A. Ginés, C. Dolz.
Linfoma gástrico tipo MALT.
Med Clin (Barc), 120 (2003), pp. 349-352
[22.]
M. Stolte, C.H. Batz, E. Bayerdorffer, S. Eidt.
Helicobacter pylori eradication in the treatment and differential diagnosis of giant folds in the corpus and fundus of the stomach.
Z Gastroenterol, 33 (1995), pp. 198-201
[23.]
P. Yeaton, H.F. Frierson Jr..
Octreotide reduces enteral protein losses in Ménétrier's disease.
Am J Gastroenterol, 88 (1993), pp. 95-98
[24.]
J.S. Burdick, E. Chung, G. Tanner, M. Sun, J.E. Paciga, J.Q. Cheng, et al.
Treatment of Ménétrier's disease with a monoclonal antibody against the epidermal growth factor receptor.
N Engl J Med, 343 (2000), pp. 1697-1701
Copyright © 2004. Elsevier España, S.L.. Todos los derechos reservados
Download PDF
Article options
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos